Cellosaurus logo
expasy logo

Cellosaurus A375-VR [2015] (CVCL_AQ00)

[Text version]
Cell line name A375-VR [2015]
Accession CVCL_AQ00
Resource Identification Initiative To cite this cell line use: A375-VR [2015] (RRID:CVCL_AQ00)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
Derived from site: In situ; Leg, skin; UBERON=UBERON_0001511.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0132 (A-375)
Sex of cell Female
Age at sampling 54Y
Category Cancer cell line
Publications

PubMed=26497853; DOI=10.18632/oncotarget.5755; PMCID=PMC4747351
Fofaria N.M., Frederick D.T., Sullivan R.J., Flaherty K.T., Srivastava S.K.
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Oncotarget 6:40535-40556(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_AQ00
Encyclopedic resources Wikidata; Q54606866
Entry history
Entry creation02-May-2016
Last entry update10-Sep-2024
Version number15